Various ongoing clinical studies focus on the combination of anti-PD-1/PD-L1 and anti-VEGF/VEGFR-2 antibodies in lung cancer (NCT02366143), hepatocellular carcinoma (NCT04102098 and NCT03434379), metastatic colorectal cancer (NCT02997228), renal cell carcinoma (NCT024420821), gastric cancer (NCT02572687), carcinoma of urethral epithelium (NCT02443324), biliary tract cancer (NCT02443324), etc. Most studies are still in early stage but encouraging efficacy has been observed in some cancer types [3,109]. Here, VEGFA is linked to renal cell carcinoma.